Literature DB >> 21729116

Pupillometry in healthy volunteers as a biomarker of tramadol efficacy.

O Matouskova1, O Slanar, L Chytil, F Perlik.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: The opioid effect of tramadol, which can be detected by pupillary response, is predominantly mediated by the O-demethylated metabolite, formed via CYP2D6. This study was designed to evaluate the effects of tramadol using different parameters of pupillometry as biomarkers.
METHODS: Sixty-nine healthy volunteers received tramadol hydrochloride drops orally at a dose of 0·7 mg/kg. Pre-dose and 2-h post-dose pupillometric measurements were performed. The polymorphism of CYP2D6 was analysed. RESULTS AND DISCUSSION: Large interindividual variability was observed in the tramadol-induced pupillary reaction. Miosis was induced in 69·6% and mydriasis in 30·4% of the subjects. The pupillary response differed in relation to the CYP2D6 genotype. A maximal difference in initial pupil diameter of 0·81 mm was found in extensive metabolizers. There were significant effects observed on the pupillary light reflex parameters with tramadol administration (P < 0·05) except for the reflex amplitude and constriction velocity. WHAT IS NEW AND
CONCLUSION: The pharmacodynamic effects of tramadol were easily detected using both static and dynamic pupil parameters. The pharmacodynamic profiles were markedly influenced by the CYP2D6 phenotype.
© 2010 The Authors. JCPT © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21729116     DOI: 10.1111/j.1365-2710.2010.01203.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  12 in total

1.  Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Authors:  William W Stoops; Michelle R Lofwall; Paul A Nuzzo; Lori B Craig; Anthony J Siegel; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

2.  Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients.

Authors:  O Bartošová; C Bonnet; O Ulmanová; M Šíma; F Perlík; E Růžička; O Slanař
Journal:  J Neural Transm (Vienna)       Date:  2017-12-19       Impact factor: 3.575

3.  Abuse liability and reinforcing efficacy of oral tramadol in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Anthony J Siegel; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2012-10-23       Impact factor: 4.492

4.  Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  Drug Metab Dispos       Date:  2016-10-06       Impact factor: 3.922

Review 5.  The Pharmacogenetics of Tramadol.

Authors:  Dorte Lassen; Per Damkier; Kim Brøsen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

Review 6.  Pupillary motility: bringing neuroscience to the psychiatry clinic of the future.

Authors:  Simona Graur; Greg Siegle
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

7.  Dysregulation of the autonomous nervous system in patients with temporomandibular disorder: a pupillometric study.

Authors:  Annalisa Monaco; Ruggero Cattaneo; Luca Mesin; Irma Ciarrocchi; Fabrizio Sgolastra; Davide Pietropaoli
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 8.  Pupillometry in perioperative medicine: a narrative review.

Authors:  Senthil Packiasabapathy; Valluvan Rangasamy; Senthilkumar Sadhasivam
Journal:  Can J Anaesth       Date:  2021-01-11       Impact factor: 6.713

9.  Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.

Authors:  Linda M Rorick-Kehn; Jennifer W Witcher; Stephen L Lowe; Celedon R Gonzales; Mary Ann Weller; Robert L Bell; John C Hart; Anne B Need; Jamie H McKinzie; Michael A Statnick; Jeffrey G Suico; David L McKinzie; Sitra Tauscher-Wisniewski; Charles H Mitch; Randall R Stoltz; Conrad J Wong
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).

Authors:  Maja Matic; Marga Nijenhuis; Bianca Soree; Nienke J de Boer-Veger; Anne-Marie Buunk; Elisa J F Houwink; Hans Mulder; Gerard A P J M Rongen; Jan van der Weide; Bob Wilffert; Jesse J Swen; Henk-Jan Guchelaar; Vera H M Deneer; Ron H N van Schaik
Journal:  Eur J Hum Genet       Date:  2021-07-15       Impact factor: 5.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.